联环药业
(600513)
| 流通市值：54.98亿 | | | 总市值：54.98亿 |
| 流通股本：2.85亿 | | | 总股本：2.85亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 810,625,785.82 | 2,711,858,051.35 | 2,082,459,109.35 | 1,285,342,346.98 |
| 营业收入 | 810,625,785.82 | 2,711,858,051.35 | 2,082,459,109.35 | 1,285,342,346.98 |
| 二、营业总成本 | 800,833,222.39 | 2,711,961,483.08 | 2,028,444,912.55 | 1,230,280,455.15 |
| 营业成本 | 595,627,162.11 | 1,768,226,292.33 | 1,364,226,995.64 | 786,613,734.42 |
| 税金及附加 | 5,292,852.48 | 21,157,729.5 | 14,655,363.82 | 10,210,703.62 |
| 销售费用 | 104,528,261.15 | 501,460,647.32 | 374,198,002.09 | 263,149,785.33 |
| 管理费用 | 58,012,271.6 | 183,718,858.1 | 143,279,509.29 | 86,783,433.5 |
| 研发费用 | 28,659,901.36 | 205,274,406.68 | 107,582,797.46 | 68,423,933.06 |
| 财务费用 | 8,712,773.68 | 32,123,549.15 | 24,502,244.25 | 15,098,865.22 |
| 其中:利息费用 | 8,370,386.24 | 32,290,196.04 | 24,491,376.61 | 15,570,894.61 |
| 其中:利息收入 | -17,715.07 | 654,232.91 | 429,638.24 | 351,738.21 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -225,812.48 | -10,155,426.27 | -2,977,730.95 | -2,292,190.27 |
| 资产处置收益 | 908.6 | -77,537.02 | - | - |
| 资产减值损失(新) | 215,067.77 | -10,860,329.06 | -923,558.06 | -927,206.48 |
| 信用减值损失(新) | -1,501,507.95 | -6,583,059.54 | 1,503,160.7 | -2,626,861.6 |
| 其他收益 | 2,701,864 | 17,380,879.02 | 7,842,433.2 | 4,031,900.88 |
| 四、营业利润 | 10,983,083.37 | -10,398,904.6 | 59,458,501.69 | 53,247,534.36 |
| 加:营业外收入 | 118,039.65 | 433,907.38 | 538,622.86 | 320,753.13 |
| 减:营业外支出 | 500,626.52 | 77,640,671 | 61,494,345.92 | 61,074,105.39 |
| 五、利润总额 | 10,600,496.5 | -87,605,668.22 | -1,497,221.37 | -7,505,817.9 |
| 减:所得税费用 | 3,238,111.33 | -3,452,873.66 | 26,225,175.05 | 24,851,779.14 |
| 六、净利润 | 7,362,385.18 | -84,152,794.56 | -27,722,396.42 | -32,357,597.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 7,362,385.18 | -84,152,794.56 | -27,722,396.42 | -32,357,597.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 6,424,752.09 | -98,332,448.41 | -35,062,142.12 | -40,028,355.46 |
| 少数股东损益 | 937,633.09 | 14,179,653.85 | 7,339,745.7 | 7,670,758.42 |
| 扣除非经常损益后的净利润 | 5,611,567.53 | -32,754,164.06 | 22,297,641.87 | 19,509,365.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | -0.34 | -0.12 | -0.14 |
| (二)稀释每股收益 | 0.02 | -0.34 | -0.12 | -0.14 |
| 八、其他综合收益 | 634,095.24 | -124,595.73 | -104,216.08 | -96,708.4 |
| 归属于母公司股东的其他综合收益 | 634,095.24 | -124,595.73 | -104,216.08 | -96,708.4 |
| 九、综合收益总额 | 7,996,480.42 | -84,277,390.29 | -27,826,612.5 | -32,454,305.44 |
| 归属于母公司股东的综合收益总额 | 7,058,847.33 | -98,457,044.14 | -35,166,358.2 | -40,125,063.86 |
| 归属于少数股东的综合收益总额 | 937,633.09 | 14,179,653.85 | 7,339,745.7 | 7,670,758.42 |
| 公告日期 | 2026-04-28 | 2026-04-21 | 2025-10-25 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |